There are currently 183 active clinical trials seeking participants for Multiple Myeloma research studies. The states with the highest number of trials for Multiple Myeloma participants are California, New York, Ohio and Texas.
Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma
NCT06179888
Recruiting
This phase II trial compares iberdomide maintenance therapy to disease monitoring for improving survival in patients who have received idecabtagene vicleucel (a type of chimeric antigen receptor T-cell \[CAR-T\] therapy) for multiple myeloma. The usual approach after treatment with idecabtagene vicleucel is to monitor the multiple myeloma without giving myeloma medications. There is currently no medication approved specifically for use after idecabtagene vicleucel treatment. Upon administration,... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California +56 locations
Conditions: Multiple Myeloma
Register for Updates
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Recruiting
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT03412877
Recruiting
Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken from the person s body, and the gene transfer occurs in a laboratory. A type of virus is used to transfer the genes that make those white blood cells able to attack the mutation in the tumor. The gene transfer therapy is the return of those white blood... Read More
Gender:
ALL
Ages:
Between 18 years and 72 years
Trial Updated:
04/04/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Endocrine Tumors, Neuroendocrine Tumors, Gastrointestinal/Genitourinary Cancers, Multiple Myeloma
Register for Updates
Implementing a Randomized Control Trial to Test the Expanded Web-based Decision Aid
NCT06910670
Recruiting
The overall goal of the randomized control trial (RCT) will be to evaluate the efficacy of modifications to a web-based tool for patient decision-making regarding return of genomic results that will more closely focus on rare cancers. Participants will be given access to a web-based decision aid (or a standard control) that guides participants in making decisions about what type of genomic results they would like to receive from testing performed in the PE-CGS study (NCT06340646).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/03/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Cholangiocarcinoma, Colorectal Cancer, Multiple Myeloma
Register for Updates
A Study of Daratumumab
NCT05438043
Recruiting
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/02/2025
Locations: University of Miami Sylvester Cancer Center, Miami, Florida +75 locations
Conditions: Multiple Myeloma
Register for Updates
In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
NCT05093335
Recruiting
The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Non-Hodgkin Lymphoma, Multiple Myeloma, Histiocytic Neoplasms, Erdheim-Chester Disease, Rosai-Dorfman Disease
Register for Updates
A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
NCT06083922
Recruiting
The purpose of this study is to find out whether cyclophosphamide, bortezomib, dexamethasone (CyBorD) with daratumumab SC is a safe treatment combination for MGRS-associated kidney disease including cast nephropathy associated with multiple myeloma. In addition, the researchers will find out whether the study drug combination is an effective treatment for these conditions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Tufts Medical Center (Data Collection Only), Boston, Massachusetts +9 locations
Conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
Register for Updates
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
NCT04822337
Recruiting
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the overall response to this study treatment combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/30/2025
Locations: Levine Cancer Institute, Charlotte, North Carolina +1 locations
Conditions: Multiple Myeloma
Register for Updates
A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
NCT05640843
Recruiting
The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: Emory University (Data Collection Only), Atlanta, Georgia +7 locations
Conditions: Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Register for Updates
Remote Monitoring with Health-Coaching to Improve Quality of Life in Older Patients with Multiple Myeloma
NCT06145581
Recruiting
This clinical trial tests the effectiveness of a home-based mindfulness physical activity program with remote monitoring combined with structured telephone-based health coaching to decrease fatigue and improve quality of life in older patients with multiple myeloma (MM). Studies have shown that MM patients have the highest symptom burden among all blood cancers, with older patients experiencing more symptoms and problems, such as fatigue and decreased quality of life, compared to younger patient... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
03/24/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Multiple Myeloma
Register for Updates
64Cu-LLP2A for Imaging Hematologic Malignancies
NCT06636175
Recruiting
This phase of the protocol (protocol part B), seeks to evaluate the new formulation in healthy normal volunteers to confirm the new formulation provides comparable human dosimetry to which was seen and published in protocol part A. Additionally, the new formulation will be studied utilizing an expanded patient population to include patients with confirmed diagnosis of multiple myeloma (MM), low-grade lymphoma, or MM and lymphoma patients who are status post bone marrow transplant (BMT) with nega... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Multiple Myeloma, Low-Grade Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
Register for Updates
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
NCT05372354
Recruiting
The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/17/2025
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +16 locations
Conditions: Multiple Myeloma
Register for Updates